Monopar Therapeutics Inc. (NASDAQ:MNPR) CFO Karthik Radhakrishnan Purchases 1,550 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) CFO Karthik Radhakrishnan bought 1,550 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was purchased at an average cost of $16.25 per share, with a total value of $25,187.50. Following the completion of the transaction, the chief financial officer now directly owns 1,550 shares in the company, valued at $25,187.50. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Monopar Therapeutics Stock Down 9.5 %

MNPR stock opened at $14.67 on Thursday. The stock’s 50 day moving average is $5.70 and its 200-day moving average is $4.19. Monopar Therapeutics Inc. has a twelve month low of $1.37 and a twelve month high of $38.50. The firm has a market capitalization of $51.64 million, a PE ratio of -6.38 and a beta of 1.26.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). On average, equities research analysts anticipate that Monopar Therapeutics Inc. will post -1.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MNPR. HC Wainwright raised their price objective on Monopar Therapeutics from $2.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Rodman & Renshaw began coverage on Monopar Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $50.00 target price on the stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.